Cobblestone Capital Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Cobblestone Capital Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,000	Closed	-$46K	–	253
2020 Q2	$46K	Hold	4,000	–	–	﹤0.01%	237
2020 Q1	$55K	Hold	4,000	–	–	0.01%	241
2019 Q4	$24K	Sell	4,000 -240	-6%	-$1.3K	﹤0.01%	254
2019 Q3	$22K	Hold	4,240	–	–	﹤0.01%	238
2019 Q2	$33K	Hold	4,240	–	–	﹤0.01%	243
2019 Q1	$84K	Hold	4,240	–	–	0.01%	241
2018 Q4	$56K	Buy	+4,240	New	+$84.7K	0.01%	232

Other funds holding KDNY

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Cobblestone Capital Advisors's KDNY Position: Q3 2020 in Review

Cobblestone Capital Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2020, closing a stake of 4,000 shares — an estimated $46K sold.

Cobblestone Capital Advisors first reported a position in KDNY in Q4 2018 and held it in 7 quarters. The position peaked at $84K in Q1 2019. 70 funds tracked by Wall St. Rank hold KDNY as of Q3 2020.

Cobblestone Capital Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Cobblestone Capital Advisors sold 4,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $46K.
Cobblestone Capital Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2018 and held it in 7 quarters.
Cobblestone Capital Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $84K in Q1 2019.
70 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Cobblestone Capital Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.